Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

New Plasmids Developed for Real-Time Monitoring of Key Intracellular Molecules

By BiotechDaily International staff writers
Posted on 28 Mar 2013
New plasmids are now available for real-time assays enabling cell biology as well as drug discovery researchers to visualize and study the in vivo action of target molecules involved in key regulatory cell processes.

ChromoTek GmbH (Munich, Germany) offers the new nanobody based “Chromobody Plasmids” to visualize and measure the action of candidate drugs or other substances of interest on important regulatory processes in living cells. Presently, four plasmids are available: for analyzing the cell cycle, apoptosis, DNA methylation, and cytoskeleton dynamics. A major advantage of the new Chromobody plasmids compared to Chromobody cell lines already available is that researchers can now monitor cellular pathways in their own cells or cell lines simply by carrying out a transfection. Unlike conventional, end-point assays, the Chromobody plasmids allow the fate of endogeneous target proteins to be followed over time, also visually in a movie-like format. Additionally, as the fluorescently labeled intracellular antibodies expressed from these plasmids do not interfere with the activity of their targets, they are extremely useful for high-content screening.

The new product format is equally suitable for academic researchers who want to decipher cellular pathways and for biotech and pharma researchers seeking to enhance their drug discovery and high-throughput screening capabilities. “We are glad to be able to offer our customers a new product format that gives them greater flexibility both in basic cell biology research and in drug discovery and validation processes,” stated Marion Jung, Managing Director of ChromoTek. Researchers who would like to try the Chromobody technology for their own applications can now choose between three options: license a cell line; order assay-ready frozen instant cells via ChromoTek or via CCS (Cell Culture Service, now part of Evotec AG); or purchase a Chromobody plasmid.

Related Links:

ChromoTek



Channels

Genomics/Proteomics

view channel
Image: Typical antibodies (left) unfold in the harsh environment of the cell. Camelid antibodies (right) are smaller and more stable (Photo courtesy of the Washington University School of Medicine).

Double Targeting Approach Increases Potential for Cancer Treatment with Oncolytic Viruses

Cancer researchers have used a double targeting approach to direct oncolytic viruses specifically to tumor cells where they reproduce until the cancer cells burst, releasing more viruses to infect and... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.